dapagliflozin

Dapagliflozin is a small molecule pharmaceutical drug in the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is primarily used to treat type 2 diabetes mellitus by lowering blood glucose levels through inhibition of SGLT2 in the kidneys, which increases urinary glucose excretion. Dapagliflozin also reduces the risk of hospitalization for heart failure and cardiovascular death in adults with heart failure or chronic kidney disease, and it helps slow progression of kidney disease. The drug was developed by AstraZeneca and first approved by regulatory agencies in 2014[1][2][5]. Its cardioprotective effects are attributed to hemodynamic changes such as osmotic diuresis and natriuresis, reducing cardiac preload and afterload[5].

Brand names

FarxigaForxiga

Other names

Dapagliflozin Viatris